Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,346
  • Shares Outstanding, K 29,802
  • Annual Sales, $ 1,420 K
  • Annual Income, $ -63,660 K
  • 60-Month Beta 1.89
  • Price/Sales 38.04
  • Price/Cash Flow N/A
  • Price/Book 2.59
Trade PLSE with:

Options Overview Details

View History
  • Implied Volatility 334.81% ( -21.33%)
  • Historical Volatility 177.64%
  • IV Percentile 98%
  • IV Rank 61.94%
  • IV High 504.98% on 05/12/22
  • IV Low 57.85% on 12/17/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 1,805
  • Open Int (30-Day) 1,891

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +35.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4050 +35.94%
on 05/12/22
2.9500 -35.25%
on 04/27/22
-1.0000 (-34.36%)
since 04/26/22
3-Month
1.4050 +35.94%
on 05/12/22
5.7400 -66.72%
on 03/18/22
-3.4800 (-64.56%)
since 02/25/22
52-Week
1.4050 +35.94%
on 05/12/22
29.1600 -93.45%
on 08/30/21
-16.2900 (-89.51%)
since 05/26/21

Most Recent Stories

More News
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pulse Biosciences, Inc. (“Pulse” or “the Company”) (NASDAQ:...

PLSE : 1.9000 (+6.15%)
Pulse Biosciences, Inc. Announces Changes to its Rights Offering

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-Pulse Stimulation™ (NPS™)...

PLSE : 1.9000 (+6.15%)
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PLSE : 1.9000 (+6.15%)
NPCE : 6.26 (+4.33%)
Pulse Biosciences Reports First Quarter 2022 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results...

PLSE : 1.9000 (+6.15%)
Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previously announced rights offering...

PLSE : 1.9000 (+6.15%)
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report...

PLSE : 1.9000 (+6.15%)
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference

Pulse Biosciences, Inc . (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that one oral...

PLSE : 1.9000 (+6.15%)
PULSE BIOSCIENCES (PLSE) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Pulse Biosciences, Inc. for Potential Securities Fraud Violations and Breaches of Fiduciary Duty

Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud violations and breach of fiduciary duty...

PLSE : 1.9000 (+6.15%)
PULSE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Pulse Biosciences, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Pulse Biosciences, Inc. (“Pulse” or the “Company”)...

PLSE : 1.9000 (+6.15%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc. (PLSE)

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 18, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Pulse Biosciences,...

PLSE : 1.9000 (+6.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 1.9955
2nd Resistance Point 1.9364
1st Resistance Point 1.8632
Last Price 1.9000
1st Support Level 1.7309
2nd Support Level 1.6718
3rd Support Level 1.5986

See More

52-Week High 29.1600
Fibonacci 61.8% 18.5576
Fibonacci 50% 15.2825
Fibonacci 38.2% 12.0074
Last Price 1.9000
52-Week Low 1.4050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar